OKYO Pharma Reports Stellar Results In Phase 2 Trial For Dry Eye Disease

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on innovative therapies for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP), a condition lacking FDA-approved therapy, has unveiled compelling new categorical data analyses from the recent OK-101 Phase 2 trial in DED patients. These analyses highlight conjunctival staining and ocular pain as the most promising "sign" and "symptom" co-primary endpoints for investigation in OK-101's next DED trial.

Gary S. Jacob, Ph.D., CEO of OKYO Pharma, “The data from this first in-human trial of OK-101 in patients with DED have established a clear road map for future clinical development in this indication. Through our analytical work we have concluded that conjunctival staining and ocular pain represent important and de-risked endpoints to be studied further to help underserved patients whose dry eye symptoms include pain components. Furthermore, this trial demonstrated a favourable tolerability profile for OK-101, with an excellent eyedrop comfort score for a topically administered drug.”

Gabriele Cerrone, Non-Executive Chairman of OKYO Pharma, commented, “Dry eye disease encompasses a diverse and dissatisfied patient population who needs treatment alternatives to available anti-inflammatory medicines which are insufficient to alleviate the broad spectrum of bothersome ocular symptoms encompassed by this condition. We continue to advance our innovative program which focuses on the segment of patients most impacted by ocular pain, and will evaluate next steps for dry eye with our advisors and the regulatory agencies.”